000			05779nam a22003855i 4500
001			76179
003			ES-MaUEC
005			20230207040212.0
007			cr nn 008mamaa
008			121211s2013 xxu| s |||| 0|eng d
020			_a9781627032001
024	7		_a10.1007/978-1-62703-200-1 _2doi
050		4	_aQH588.S83 _bM47 2013 EB
082	0	4	_a571.6
245	0	0	_aMesenchymal Stem Cell Therapy _cedited by Lucas G. Chase, Mohan C. Vemuri
260			_aTotowa, NJ _bHumana Press _c2013
300			_a1 recurso en línea (XII, 453 p.) _b32 ilustraciones, 20 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	1		_aStem Cell Biology and Regenerative Medicine
505	0		_aScaling-up Ex-vivo Expansion of Mesenchymal Stem/Stromal Cells for Cellular Therapies -- Mesenchymal Stromal Cell Mechanisms of Immunomodulation and Homing -- Mesenchymal Stem Cell Exosomes: The Future MSC-based Therapy? -- The Biology of Mesenchymal Stem Cells in Health and Disease and its Relevance to MSC-based Cell Delivery Therapies -- Pulmonary Clinical Applications for Mesenchymal Stem Cells -- Stem Cell Therapy for Bone Disorders -- Mesenchymal Stem Cell Therapies for Bone and Tendon Conditions -- Mesenchymal Stromal Cells (MSC) and the Repair of Cartilage Tissue -- Mesenchymal Stem Cells and Haematopoietic Stem Cell Culture -- Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus-Host Disease and Graft Failure after Hematopoietic Stem Cell Transplantation and Future Challenges -- Mesenchymal Stromal Cell Therapy in Crohnâ Disease -- Application of Mesenychymal Stem Cells in Amyotrophic Lateral Sclerosis -- Mesenchymal Stem Cell Therapy for Heart Disease -- Advances in Lentivector-based Cell Therapy with Mesenchymal Stem Cells -- Genetically Engineered Mesenchymal Stem Cells for Cell and Gene Therapy -- Optimal Tissue Sources of Mesenchymal Stromal Cells for Clinical Trials -- Regulatory Considerations Applicable to Manufacturing of Human Placenta-derived Mesenchymal Stromal Cells (MSC) Used in Clinical Trials in Australia and Comparison to USA and European Regulatory Frameworks -- Mesenchymal Stem Cell Therapy for Peripheral Vascular Diseases -- Mesenchymal Stromal Cells in the Clinic: What do the clinical trials say?.
520	3		_aOver the past decade, significant efforts have been made to develop stem cell-based therapies for difficult to treat diseases. Multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSCs), appear to hold great promise in regards to a regenerative cell-based therapy for the treatment of these diseases. Currently, more than 200 clinical trials are underway worldwide exploring the use of MSCs for the treatment of a wide range of disorders including bone, cartilage and tendon damage, myocardial infarction, graft-versus-host disease, Crohn{u2019}s disease, diabetes, multiple sclerosis, critical limb ischemia and many others. MSCs were first identified by Friendenstein and colleagues as an adherent stromal cell population within the bone marrow with the ability to form clonogenic colonies in vitro. In regards to the basic biology associated with MSCs, there has been tremendous progress towards understanding this cell population{u2019}s phenotype and function from a range of tissue sources. Despite enormous progress and an overall increased understanding of MSCs at the molecular and cellular level, several critical questions remain to be answered in regards to the use of these cells in therapeutic applications. Clinically, both autologous and allogenic approaches for the transplantation of MSCs are being explored. Several of the processing steps needed for the clinical application of MSCs, including isolation from various tissues, scalable in vitro expansion, cell banking, dose preparation, quality control parameters, delivery methods and numerous others are being extensively studied. Despite a significant number of ongoing clinical trials, none of the current therapeutic approaches have, at this point, become a standard of care treatment. Although exceptionally promising, the clinical translation of MSC-based therapies is still a work in progress. The extensive number of ongoing clinical trials is expected to provide a clearer path forward for the realization and implementation of MSCs in regenerative medicine. Towards this end, reviews of current clinical trial results and discussions of relevant topics association with the clinical application of MSCs are compiled in this book from some of the leading researchers in this exciting and rapidly advancing field. Although not absolutely all-inclusive, we hope the chapters within this book can promote and enable a better understanding of the translation of MSCs from bench-to-bedside and inspire researchers to further explore this promising and quickly evolving field
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGERrevisando
650		7	_aCélulas madre _0comprobar BNE20022110396 _2embne _9160528
650		7	_aCitología _0comprobar BNE19900972907 _2embne _9139477
700	1		_aChase, Lucas G. _eeditor literario _985100 _0Local
700	1		_aVemuri, Mohan C. _eeditor literario _985101 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-62703-200-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_aocn9781627032001
907			_a.b12817971 _b10-10-17 _c01-10-14
998			_am _a_alco _a_vill _b31-05-17 _cm _dz _ek _feng _gxxu _h0
945			_aQH588.S83 M47 2013 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11547194 _z06-04-17
999			_c76179 _d76179 _x1